CDIP Antibody | 5059

CDIP Antibody | 5059 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: Predicted species reactivity based on immunogen sequence: Rat: (100%) , Bovine: (100%)

Immunogen: CDIP antibody was raised against a 19 amino acid synthetic peptide near the center of human CDIP.
The immunogen is located within amino acids 70 - 120 of CDIP.

Research Area: Apoptosis

Tested Application: E, WB, IHC-P, IF

Application: CDIP antibody can be used for detection of CDIP by Western blot at 0.25 - 0.5 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1303 - Human Brain Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: CDIP Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CDIP Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: CDIP antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CDIP Antibody: I1, CDIP, LITAFL, C16orf5, Cell death-inducing p53-target protein 1, Cell death involved p53-target

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CDIP Antibody: The p53 tumor-suppressor gene integrates numerous signals that control cell life and death; loss of its functions contributes to the development of most cancers. CDIP is a novel pro-apoptotic target gene whose inhibition abrogates p53-mediated apoptotic responses. Overexpression of CDIP induced apoptosis in transfected cells while siRNA suppression of caspase-8 mRNA blocked this CDIP-induced apoptosis, indicating that the CDIP-dependent apoptosis pathway proceeds through extrinsic cell death pathway. CDIP may thus represent a novel target for drug design to maximize p53 response and sensitize tumor cells to cancer therapy. Multiple isoforms of CDIP are known to exist.